NASDAQ:CTRV - ContraVir Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.52
▼ -0.02 (-1.30%)
Get New ContraVir Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTRV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTRV

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ContraVir Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.52.

This chart shows the closing price for CTRV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in ContraVir Pharmaceuticals. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2019Maxim GroupDowngradeBuy ➝ HoldMedium
7/10/2018Maxim GroupUpgradeHold ➝ BuyLow
6/14/2018Maxim GroupReiterated RatingHoldMedium
5/30/2018Maxim GroupReiterated RatingHoldMedium
4/13/2018Maxim GroupReiterated RatingHoldMedium
2/13/2018Maxim GroupDowngradeBuy ➝ HoldLow
2/12/2018Maxim GroupSet Price TargetBuy$32.00High
10/30/2017Maxim GroupSet Price TargetBuy$32.00N/A
10/19/2017Maxim GroupSet Price TargetBuy$32.00N/A
8/24/2017Maxim GroupReiterated RatingBuy$32.00Low
4/21/2017Noble FinancialReiterated RatingBuyHigh
4/11/2017Maxim GroupSet Price TargetBuy$32.00Low
4/7/2017Noble FinancialReiterated RatingBuyMedium
4/4/2017Maxim GroupReiterated RatingBuy$32.00High
2/14/2017Maxim GroupReiterated RatingBuy$32.00N/A
12/8/2016Maxim GroupSet Price TargetBuy$32.00N/A
(Data available from 10/18/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/18/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ContraVir Pharmaceuticals logo
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.
Read More

Today's Range

Now: $1.52
Low: $1.49
High: $1.55

50 Day Range

MA: $3.11
Low: $2.53
High: $3.58

52 Week Range

Now: $1.52
Low: $3.52
High: $91.00

Volume

559,240 shs

Average Volume

432,822 shs

Market Capitalization

$1.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of ContraVir Pharmaceuticals?

The following sell-side analysts have issued reports on ContraVir Pharmaceuticals in the last year:
View the latest analyst ratings for CTRV.

What is the current price target for ContraVir Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for ContraVir Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ContraVir Pharmaceuticals in the next year.
View the latest price targets for CTRV.

What is the current consensus analyst rating for ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CTRV.

What other companies compete with ContraVir Pharmaceuticals?

How do I contact ContraVir Pharmaceuticals' investor relations team?

ContraVir Pharmaceuticals' physical mailing address is 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837. The biopharmaceutical company's listed phone number is 732-902-4000 and its investor relations email address is [email protected] The official website for ContraVir Pharmaceuticals is www.contravir.com.